FDA Clarifies How Drug Sponsors Can Demonstrate Effectiveness

Overview

The U.S. Food and Drug Administration (FDA) has issued a revised draft guidance for industry titled Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products, providing updated recommendations on how sponsors can establish effectiveness in support of new drug applications (NDAs), biologics license applications (BLAs), and certain supplemental applications.

The revised draft guidance reflects significant changes in drug development since FDA’s original 1998 guidance. It incorporates lessons learned from advances in biological science, precision medicine, clinical trial methodology, and the growing availability of high-quality data sources.

At its core, the guidance signals that FDA’s focus is increasingly on the overall strength, quality, and persuasiveness of evidence rather than simply counting the number of clinical trials conducted.

For sponsors, regulatory affairs professionals, clinical researchers, and drug development teams, the document provides important insight into how FDA is thinking about modern evidence generation and regulatory decision-making.

Why FDA Updated the Guidance

FDA explains that the evidentiary landscape for drug development has changed substantially over the last several decades.

According to the agency, advances in scientific understanding, disease characterization, biomarkers, analytical methods, and data collection have created new opportunities to generate rigorous evidence more efficiently than was possible when the 1998 guidance was published.

As a result, FDA revised the guidance to provide a clearer framework for evaluating evidence of effectiveness in today’s development environment.

Importantly, FDA emphasizes that the substantial evidence standard itself has not changed. What has evolved is the agency’s understanding of how evidence may be generated and evaluated in support of that standard.

The Bigger Story: FDA Is Adapting to Modern Evidence Generation

One of the most important themes in the revised draft guidance is that FDA is recognizing the increasing sophistication of modern drug development.

Historically, substantial evidence of effectiveness was often associated with the expectation of two adequate and well-controlled clinical investigations. While FDA’s authority to rely on one adequate and well-controlled investigation plus confirmatory evidence has existed for many years, the agency now provides a more comprehensive discussion of how this approach may be applied across a broader range of development programs.

The guidance reflects FDA’s view that the strength of an evidence package is not determined solely by the number of trials conducted. Instead, the agency emphasizes factors such as trial quality, scientific rigor, clinical relevance, statistical persuasiveness, confirmatory evidence, and the overall development program.

In practical terms, the draft guidance suggests that sponsors should focus less on meeting a perceived numerical expectation and more on building a scientifically compelling case that demonstrates effectiveness.

What “Substantial Evidence of Effectiveness” Means

To approve a drug, FDA must determine that substantial evidence supports the product’s effectiveness.

The guidance explains that substantial evidence consists of adequate and well-controlled investigations conducted by qualified experts that allow those experts to conclude that a drug will have the effect it purports to have under the proposed conditions of use.

FDA also notes that substantial evidence is necessary but not sufficient for approval. The agency must separately determine that the product is safe for its intended use and that its benefits outweigh its risks.

This distinction is important because a development program may successfully demonstrate effectiveness while still requiring additional safety information before approval can be granted.

One Adequate and Well-Controlled Trial Plus Confirmatory Evidence

A central focus of the revised draft guidance is FDA’s discussion of one adequate and well-controlled clinical investigation supported by confirmatory evidence. FDA clarifies that a single trial is not automatically sufficient.

Rather, sponsors relying on a single adequate and well-controlled investigation must provide confirmatory evidence, and the quantity and quality of that evidence may vary depending on the strength of the primary clinical investigation.

The revised draft guidance removes prior discussion suggesting that one trial is the legal or scientific equivalent of two trials. FDA explains that this framing may have created confusion regarding regulatory expectations. Instead, the agency focuses on the overall evidentiary package and the persuasiveness of the evidence supporting effectiveness.

For sponsors, this reinforces the importance of thinking strategically about how they will generate confirmatory evidence throughout a development program.

Factors That Impact the Strength of Evidence

The revised draft guidance identifies multiple factors that may affect the strength of evidence supporting effectiveness.

These include:

• Trial design
• Trial conduct
• Trial analysis plans
• Clinical relevance of endpoints
• Statistical persuasiveness of results
• Characteristics of the overall development program
• Sources of confirmatory evidence

FDA repeatedly emphasizes that no single factor determines whether substantial evidence has been demonstrated. Instead, the strength of evidence depends on the totality of information available to support a regulatory decision.

This holistic approach reflects the complexity of modern drug development and the need to evaluate evidence in context.

Trial Design Remains Critical

Although FDA acknowledges evolving approaches to evidence generation, the agency continues to stress the importance of well-designed clinical investigations.

The guidance highlights key design elements such as:

• Appropriate control selection
• Randomization
• Blinding
• Reliable endpoints
• Participant selection
• Robust statistical analysis methods

FDA explains that these elements help distinguish the effect of a drug from other influences, including placebo effects, spontaneous disease changes, and biased observations.

The agency also discusses non-inferiority trials, active-control designs, placebo-controlled trials, and externally controlled studies, noting that the strength of evidence from these approaches depends heavily on the validity of underlying assumptions and the potential for bias.

Regulatory Flexibility Still Has a Role

FDA retains discussion regarding the application of regulatory flexibility in certain circumstances.

The agency acknowledges that in some settings, including serious diseases, rare diseases, and conditions with limited treatment options, greater uncertainty may be acceptable when balanced against the potential consequences of delaying or denying access to a beneficial therapy.

However, flexibility does not eliminate the need for rigorous evidence. Instead, it places greater importance on scientific justification, development strategy, and the overall strength of the evidence package.

Why This Matters for Sponsors and Development Teams

For sponsors, the revised draft guidance has implications far beyond clinical trial design.

The document encourages development teams to think strategically about how evidence will be accumulated, integrated, and justified throughout a development program.

FDA specifically recommends discussing plans for demonstrating substantial evidence of effectiveness early in development, ideally at a pre-IND meeting and no later than the end-of-phase 2 meeting.

These discussions should include a clear scientific rationale supporting the proposed evidence-generation strategy.

Organizations that engage FDA early and align their development programs with the agency’s evidentiary expectations may be better positioned to avoid costly delays and regulatory uncertainty later in development.

What Changed From Prior Guidance?

FDA identifies several significant changes from earlier versions of the guidance.

Key updates include:

• Streamlined discussion of the history of the substantial evidence standard.
• Removal of language suggesting one trial is the equivalent of two trials.
• Expanded discussion regarding one adequate and well-controlled investigation plus confirmatory evidence.
• Greater emphasis on factors affecting the strength of evidence across diverse development programs.
• Updated recommendations reflecting advances in science and data availability.

When finalized, the guidance is expected to replace FDA’s 1998 guidance on clinical evidence of effectiveness.

Action Items for Sponsors and Research Organizations

Review Current Evidence-Generation Strategies – Evaluate whether development programs are designed to generate evidence that is scientifically rigorous, clinically meaningful, and capable of supporting effectiveness conclusions.

Reassess Confirmatory Evidence Plans – Organizations considering reliance on one adequate and well-controlled investigation should evaluate whether planned confirmatory evidence will be sufficient to support the overall evidence package.

Engage FDA Early – Take advantage of opportunities to discuss evidence-generation strategies with FDA early in the development process.

Evaluate Trial Design Assumptions – Review decisions relating to controls, endpoints, randomization, blinding, follow-up procedures, and statistical analysis plans.

Align Cross-Functional Teams – Clinical, statistical, regulatory, medical, and operational teams should share a common understanding of how each study contributes to the overall effectiveness narrative.

Consider Submitting Comments – FDA is accepting comments on the revised draft guidance through September 22, 2026.

How To Submit Comments

Submit comments electronically through Regulations.gov. FDA notes that electronic submissions will generally be posted publicly and should not contain confidential information that commenters do not wish to disclose.

Why Should You Care?

This guidance addresses one of the most fundamental questions in drug and biologic development: What evidence is sufficient to demonstrate that a product works?

The document offers important insight into how FDA is adapting long-standing regulatory standards to a modern environment characterized by improved scientific understanding, new data sources, and increasingly sophisticated development programs.

For sponsors, the guidance may influence study design, development strategy, regulatory interactions, and submission planning.

For clinical researchers, it reinforces the importance of rigorous study design and high-quality evidence generation.

For regulatory professionals, it provides a clearer understanding of how FDA evaluates the strength of evidence supporting effectiveness claims.

Looking Ahead

The revised guidance remains a draft and does not establish legally enforceable requirements. FDA states that it represents the agency’s current thinking and invites stakeholder comments before finalization.

Nevertheless, the document offers valuable insight into FDA’s evolving approach to evaluating evidence of effectiveness.

Organizations involved in drug and biologic development should review the guidance carefully, assess how it may affect development strategies, and consider whether submitting comments could help shape the final version.